Talazoparib with enzalutamide

Phase 2

PProstate Cancer Clinical Trials Consortium

Talazoparib with enzalutamide is one of 2 therapeutic programs targeting Prostate Cancer (Adenocarcinoma). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostate Cancer (adenocarcinoma)Recruiting

Prostate Cancer (adenocarcinoma)Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Prostate Cancer (adenocarcinoma)

#DrugCompanyPhaseTrials

Talzenna

Pfizer

Phase 2

1 2

Talazoparib with enzalutamide

PProstate Cancer Clinical Trials Consortium

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Prostate Cancer (adenocarcinoma)

NCT06844383

Clinical

Trials by Indication[1]

Prostate Cancer (Adenocarcinoma)1 trial

A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate

Recruiting·PProstate Cancer Clinical Trials Consortium·Phase 2·NCT06844383·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Talazoparib with enzalutamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Talazoparib with enzalutamide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Prostate Cancer Clinical Trials Consortium company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: PProstate Cancer Clinical Trials Consortium

Talazoparib with enzalutamide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Prostate Cancer (Adenocarcinoma)1 trial

References

Drug Info

Quick Facts

Related News